Details of the Drug
General Information of Drug (ID: DMRVH2S)
| Drug Name |
BRECANAVIR
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Brecanavir; 313682-08-5; UNII-E367I8C7FI; GW64085X; GW640385; E367I8C7FI; CHEMBL206031; VX-385; GW0385; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL [(1S,2R)-3-[(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO]-2-HYDROXY-1-{4-[(2-METHYL-1,3-THIAZOL-4-YL)METHOXY]BENZYL}PROPYL]CARBAMATE; [3H]GW0385; Brecanavir [USAN:INN]; Proteinase inhibitor 640385; 2fde; 2fdd; Brecanavir (USAN); GSK 640385; GW 0385; AC1NX470; SCHEMBL1533991; BDBM4685; DTXSID10185296; JORVRJNILJXMMG-OLNQLETPSA-N; ZINC3994828; VX 385; AKOS005145761; DB04887; D03253
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Affected Organisms |
Human Immunodeficiency Virus
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 3 | Molecular Weight (mw) | 703.8 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.4 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 15 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 13 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
References


